{"result": "(\"entity\"<|>CYSTIC FIBROSIS<|>EVENT<|>Cystic fibrosis is a genetic disorder that affects the lungs and digestive system, leading to severe respiratory and nutritional challenges.)\n##\n(\"entity\"<|>OLIVEIRA G<|>PERSON<|>Oliveira G is a researcher involved in studies related to cystic fibrosis and its nutritional aspects.)\n##\n(\"entity\"<|>OLIVEIRA C<|>PERSON<|>Oliveira C is a researcher who has contributed to the understanding of dietary supplementation in cystic fibrosis patients.)\n##\n(\"entity\"<|>ACOSTA E<|>PERSON<|>Acosta E is a researcher who has studied the effects of fatty acid supplementation in adults with cystic fibrosis.)\n##\n(\"entity\"<|>ESPÍLDORA F<|>PERSON<|>Espíldora F is a researcher involved in the study of respiratory and inflammatory parameters in cystic fibrosis patients.)\n##\n(\"entity\"<|>GARRIDO-SÁNCHEZ L<|>PERSON<|>Garrido-Sánchez L is a researcher who has worked on nutritional parameters in cystic fibrosis.)\n##\n(\"entity\"<|>GARCÍA-ESCOBAR E<|>PERSON<|>García-Escobar E is a researcher contributing to the understanding of cystic fibrosis and its treatment.)\n##\n(\"entity\"<|>MARTINEZ-GARCIA MA<|>PERSON<|>Martinez-Garcia MA is a researcher who has studied the association between bronchiectasis and systemic inflammation in cystic fibrosis patients.)\n##\n(\"entity\"<|>PERPINA-TORDERA M<|>PERSON<|>Perpina-Tordera M is a researcher involved in studies related to cystic fibrosis and its complications.)\n##\n(\"entity\"<|>ROMAN-SANCHEZ P<|>PERSON<|>Roman-Sanchez P is a researcher who has contributed to the understanding of cystic fibrosis and its effects on health.)\n##\n(\"entity\"<|>SOLER-CATALUNA JJ<|>PERSON<|>Soler-Cataluna JJ is a researcher studying the impact of systemic inflammation in cystic fibrosis patients.)\n##\n(\"entity\"<|>CYSTIC FIBROSIS FOUNDATION<|>ORGANIZATION<|>The Cystic Fibrosis Foundation is an organization dedicated to funding research and providing support for individuals with cystic fibrosis.)\n##\n(\"entity\"<|>ARCH BRONCONEUMOL<|>ORGANIZATION<|>Arch Bronconeumol is a medical journal that publishes research related to respiratory diseases, including cystic fibrosis.)\n##\n(\"entity\"<|>NUTR CLIN MED<|>ORGANIZATION<|>Nutr Clin Med is a journal focusing on clinical nutrition, including studies related to cystic fibrosis.)\n##\n(\"entity\"<|>J CYST FIBROS<|>ORGANIZATION<|>J Cyst Fibros is a journal that publishes research specifically on cystic fibrosis and related topics.)\n##\n(\"entity\"<|>COCHRANE DATABASE<|>ORGANIZATION<|>The Cochrane Database is a collection of systematic reviews that provide evidence-based information on various health topics, including cystic fibrosis.)\n##\n(\"relationship\"<|>OLIVEIRA G<|>CYSTIC FIBROSIS<|>Oliveira G has conducted research on the nutritional aspects of cystic fibrosis, contributing to the understanding of the disease<|>7)\n##\n(\"relationship\"<|>OLIVEIRA C<|>CYSTIC FIBROSIS<|>Oliveira C has studied dietary supplementation in cystic fibrosis patients, which is crucial for their management<|>7)\n##\n(\"relationship\"<|>ACOSTA E<|>CYSTIC FIBROSIS<|>Acosta E's research on fatty acid supplementation is relevant to improving health outcomes in cystic fibrosis patients<|>7)\n##\n(\"relationship\"<|>ESPÍLDORA F<|>CYSTIC FIBROSIS<|>Espíldora F's work on respiratory parameters is significant for understanding cystic fibrosis complications<|>7)\n##\n(\"relationship\"<|>GARRIDO-SÁNCHEZ L<|>CYSTIC FIBROSIS<|>Garrido-Sánchez L's research on nutritional parameters is essential for managing cystic fibrosis<|>7)\n##\n(\"relationship\"<|>GARCÍA-ESCOBAR E<|>CYSTIC FIBROSIS<|>García-Escobar E's contributions to cystic fibrosis research help in understanding treatment options<|>7)\n##\n(\"relationship\"<|>MARTINEZ-GARCIA MA<|>CYSTIC FIBROSIS<|>Martinez-Garcia MA's studies on bronchiectasis and inflammation are important for cystic fibrosis patients<|>7)\n##\n(\"relationship\"<|>PERPINA-TORDERA M<|>CYSTIC FIBROSIS<|>Perpina-Tordera M's research contributes to the understanding of cystic fibrosis complications<|>7)\n##\n(\"relationship\"<|>ROMAN-SANCHEZ P<|>CYSTIC FIBROSIS<|>Roman-Sanchez P's work is relevant to the health impacts of cystic fibrosis<|>7)\n##\n(\"relationship\"<|>SOLER-CATALUNA JJ<|>CYSTIC FIBROSIS<|>Soler-Cataluna JJ's research on inflammation is significant for cystic fibrosis management<|>7)\n##\n(\"relationship\"<|>CYSTIC FIBROSIS FOUNDATION<|>CYSTIC FIBROSIS<|>The Cystic Fibrosis Foundation supports research and treatment for cystic fibrosis patients<|>9)\n##\n(\"relationship\"<|>ARCH BRONCONEUMOL<|>CYSTIC FIBROSIS<|>Arch Bronconeumol publishes research relevant to cystic fibrosis, contributing to medical knowledge<|>8)\n##\n(\"relationship\"<|>NUTR CLIN MED<|>CYSTIC FIBROSIS<|>Nutr Clin Med publishes studies that are important for the nutritional management of cystic fibrosis<|>8)\n##\n(\"relationship\"<|>J CYST FIBROS<|>CYSTIC FIBROSIS<|>J Cyst Fibros focuses on research specifically related to cystic fibrosis<|>9)\n##\n(\"relationship\"<|>COCHRANE DATABASE<|>CYSTIC FIBROSIS<|>The Cochrane Database provides systematic reviews that include evidence on cystic fibrosis treatments<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: al. Vitamin K status among \nchildren with cystic fibrosis and its relationship to\n\nbone mineral density and bone turnover. Pedia-\ntrics 2005; 115:1325–31.\n\n65. Olveira G, Olveira C, Acosta E, Espíldora F, Garri-\ndo-Sánchez L, García-Escobar E, et al. Fatty Acid \nSupplementation Improves Respiratory, Inflam-\nmatory and Nutritional Parameters in Adults with \nCystic Fibrosis. Arch. Bronconeumol. ((English \nEd.2010; 46:70–7.\n\n66. Olveira G, Acosta E, Olveira C. Nutrición y fibrosis \nquística: papel de la suplementación dietética con \nácidos grasos. Nutr Clin Med 2007; 1:40–51.\n\n67. Martinez-Garcia MA, Perpina-Tordera M, Ro-\nman-Sanchez P, Soler-Cataluna JJ, Carratala A, \nYago M, et al. [The association between bron-\nchiectasis, systemic inflammation, and tumor ne-\ncrosis factor alpha]. Arch Bronconeumol 2008; \n44:8–14. Available from: http://www.ncbi.nlm.\nnih.gov/pubmed/18221721.\n\n68. Sermet-Gaudelus I, Delion M, Durieu I, Jacquot J, \nHubert D. Bone demineralization is improved by \nivacaftor in patients with cystic fibrosis carrying \nthe p.Gly551Asp mutation. 2016.\n\n69. Dal Negro RW, Bonadiman L, Turco P. Prevalence \nof different comorbidities in COPD patients by \ngender and GOLD stage. Multidiscip Respir Med \n2015; 10:24. Available from: http://www.ncbi.\nnlm.nih.gov/pubmed/26246895.\n\n70. Sinaasappel M, Stern M, Littlewood J, Wolfe S, \nSteinkamp G, Heijerman HG, et al. Nutrition in pa-\ntients with cystic fibrosis: a European Consensus. J \nCyst Fibros 2002; 1:51–75. Available from: http://\nwww.ncbi.nlm.nih.gov/pubmed/15463811.\n\n71. Green D, Carson K, Leonard A, Davis JE, Rosenstein \nB, Zeitlin P, et al. Current Treatment Recommen-\ndations for Correcting Vitamin D Deficiency in Pe-\ndiatric Patients with Cystic Fibrosis Are Inadequa-\nte. J Pediatr 2008; 153:554–559.e2. Available \nfrom: http://linkinghub.elsevier.com/retrieve/pii/\nS0022347608003685.\n\n72. Tangpricha V, Kelly A, Stephenson A, Maguiness \nK, Enders J, Robinson KA, et al. An update on the \nscreening, diagnosis, management, and treatment \nof vitamin D deficiency in individuals with cystic \nfibrosis: Evidence-based recommendations from \nthe cystic fibrosis foundation. J Clin Endocrinol \nMetab 2012; 97:1082–93.\n\n73. Woestenenk JW, Broos N, Stellato RK, Arets HGM, \nvan der Ent CK, Houwen RHJ. Vitamin A intake and \nserum retinol levels in children and adolescents \nwith cystic fibrosis. Clin Nutr 2016; 35:654–9.\n\n74. Va J, Fedorowicz Z, Thaker V, Ab C. Vitamin K su-\npplementation for cystic fibrosis ( Review ). Co-\nchrane Database Syst Rev 2013.\n\n75. Oliver C, Watson H. Omega-3 fatty acids for cystic \nfibrosis. Cochrane database Syst Rev 2016; \n1:CD002201. Available from: http://www.ncbi.\nnlm.nih.gov/pubmed/26730723.\n---\n578     BLOQUE: PATOLOGÍAS ESPECÍFICAS\n\n76. Munck A, Duhamel J-F, Lamireau T, Le Luyer B, Le Tallec C, Bellon G, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibros 2009; 8:14–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18718819.\n\n77. Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H, et al. Liprotamase Long-term Safety and Support of Nutritional Status in Pancreatic-insufficient Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2012; 54:248–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22266487.\n\n78. Smyth RL, Rayner O. Oral calorie supplements for cystic fibrosis. Cochrane database Syst Rev 2014; 11:CD000406. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25363148.\n\n79. Woestenenk JW, Castelijns SJAM, van der Ent CK, Houwen RHJ. Nutritional intervention in patients with Cystic Fibrosis: A systematic review. J. Cyst. Fibros.2013; 12.\n\n80. Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. Cochrane database Syst Rev\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}